Adult Dosing

Conjunctivitis and other superficial ocular infection

Ophthalmic solution

• Initial: Instill 1-2 gtts in affected eye(s) q2-3hrs
• Taper dose by decreasing frequency with improvement of condition
• Treat for 7-10 days

Ophthalmic ointment

• Apply 0.5 inch ribbon in conjunctival sac of affected eye(s) q3-4 hrs HS
• Taper dose by decreasing frequency with improvement of condition
• Treat for 7-10 days

Trachoma adjunct to systemic therapy

Ophthalmic solution

• 2 gtts in affected eye(s) q2hrs with systemic therapy

Pediatric Dosing

• Safety and effectiveness in children age <2 months have not been established

Conjunctivitis and other superficial ocular infection

Child > = 2 months; ophthalmic solution

• Initial: Instill 1-2 gtts in affected eye(s) q2-3hrs
• Taper dose by decreasing frequency with improvement of condition
• Treat for 7-10 days

Child > = 2 months; ophthalmic ointment

• Apply 0.5 inch ribbon in conjunctival sac of affected eye(s) q3-4 hrs HS
• Taper dose by decreasing frequency with improvement of condition
• Treat for 7-10 days

Trachoma adjunct to systemic therapy

Child > = 2 months; ophthalmic solution

• 2 gtts in affected eye(s) q2hrs with systemic therapy

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of conjunctivitis and other superficial ocular infections
• Adjunct to systemic sulfonamide therapy of trachoma

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to Sulfonamide's

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Not for injection, for topical eye use only
• Fatalities reported from severe reactions to sulfonamides (eg. toxic epidermal necrolysis, Stevens-Jonson syndrome, agranulocytosis, fulminant hepatic necrosis, aplastic anemia and other blood dyscrasias). Discontinue use immediately at the first sign of rash or allergic reaction
• Prolonged administration may cause overgrowth of nonsusceptible organisms including fungi
• Use of ophthalmic ointments may retard corneal wound healing

Cautions: Use cautiously in

• Hypersensitivity to sulfonamides
• silver ophthalmic preparations

Supplemental Patient Information

• To prevent contamination, do not touch the tip to any surface, including the eye

Pregnancy Category:C

Breastfeeding: Safety unknown; according to the manufacturer data, systemically administered sulfonamides could result in producing kernicterus in infants of lactating women. Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.

• EENT: Bacterial and fungal corneal ulcer, local irritation, stinging, burning, non-specific conjunctivitis, conjunctival hyperemia, secondary infections
• HYPERSENSITIVITY: Allergic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis
• GI: Fulminant hepatic necrosis
• HEMA: Agranulocytosis, aplastic anemia, other blood dyscrasias

• Sulfonamide; inhibit bacterial synthesis of dihydrofolic acid by avoiding the condensation of the pteridine with aminobenzoic acid via competitive inhibition of the enzyme dihydropteroate synthetase
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Bleph 10

US Availability

sulfacetamide (generic)

• OPTH SOLN: 10% (15 mL)

Bleph 10

• OPTH SOLN: 10% (10 mL)

Cetamide

• OPTH OINT: 10% (3.5 g)

Canadian Trade Name(s)

• AK sulf
• Diosulf
• Sodium sulamyd

Canadian Availability

PMS sulfacetamide SOD (generic)

• OPTH SOLN: 10%, 30%

AK sulf, Diosulf, Sodium sulamyd

• OPTH SOLN: 10%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Bleph 10

Australian Availability

• OPTH SOLN: 10% (15 mL)

[Outline]

Hematology/Oncology

Hemostatic Agent

Coagulation Modifiers

Cardiovascular

Hemostatic Agent

Coagulation Modifiers